Nykode Therapeutics restructures employee share option program

Nykode Therapeutics granted 12.8m share options to employees, with 8.25m allocated to primary insiders. The options have a NOK 7.00 strike price, five-year term, and vest over four years.

The company simultaneously cancelled 7.4m previously granted options, including 6.1m held by primary insiders, representing substantially all outstanding options prior to the new grant.

Chief executive Michael Engsig received 3m options, chief scientific officer Agnete B. Fredriksen received 3m options, chief financial officer Harald Gurvin received 1.25m options, and chief technology officer Ulrich Blaschke received 1m options.